MannKind Corp (NASDAQ:MNKD)

CAPS Rating: 2 out of 5

A biopharmaceutical company focused on the development and commercialization of therapeutic products for diseases such as diabetes and cancer.

Recs

0
Player Avatar Lumentium (< 20) Submitted: 1/13/2011 6:23:32 AM : Underperform Start Price: $9.27 MNKD Score: +84.25

not enough disclosures to say otherwise

Featured Broker Partners


Advertisement